GeneDx rises after Piper Sandler initiates coverage with 'overweight' rating
View all comments(0)
Rare disease diagnostics company GeneDx WGS.O shares up ~8.9% at $92.8
Piper Sandler initiates coverage on WGS with "overweight" rating, saying the company has a unique first-mover advantage in a fast-growing and expanding market in rare disease testing
WGS has high penetration rates among key clinician types, including an 80% market share among genetics experts and 13% among pediatric neurologists - brokerage
Piper Sandler sets PT at $110, implying a ~29% upside to stock's last close
Six of seven brokerages rate the stock "buy" or higher, one "hold"; median PT is $105 - data compiled by LSEG
Including session's moves, stock up ~20.8% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Like
Recommended Articles
Featured Tools
Top News
'Big Short' Burry Doubles Down: Nvidia, Palantir Short Positions Double in Big Bet on AI Bubble Bursting

Is Micron the Next Nvidia? Why the 2026 "Memory Crunch" Makes MU Stock a Top AI Buy

Cerebras Systems IPO 2026: Date, Price, Valuation, and Whether CBRS Is Worth Buying

U.S. April CPI Preview: Fed May Abandon Rate Cuts Until 2026?

Hantavirus Appears Sporadically, Is Now the Opportunity to Buy Vaccine Concept Stock Moderna?

Tradingkey






Comments (0)
Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.